CRBP vs. ORGS, CEMI, TNXP, PTGX, AMRX, JANX, DCPH, BHC, SNDX, and CPRX
Should you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Orgenesis (ORGS), Chembio Diagnostics (CEMI), Tonix Pharmaceuticals (TNXP), Protagonist Therapeutics (PTGX), Amneal Pharmaceuticals (AMRX), Janux Therapeutics (JANX), Deciphera Pharmaceuticals (DCPH), Bausch Health Companies (BHC), Syndax Pharmaceuticals (SNDX), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical preparations" industry.
Orgenesis (NASDAQ:ORGS) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, community ranking, earnings, institutional ownership, analyst recommendations, risk and profitability.
Corbus Pharmaceuticals received 435 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 66.46% of users gave Corbus Pharmaceuticals an outperform vote.
22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 5.7% of Orgenesis shares are owned by company insiders. Comparatively, 4.0% of Corbus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Corbus Pharmaceuticals has higher revenue and earnings than Orgenesis.
Corbus Pharmaceuticals has a net margin of 0.00% compared to Corbus Pharmaceuticals' net margin of -1,343.97%. Corbus Pharmaceuticals' return on equity of 0.00% beat Orgenesis' return on equity.
Orgenesis has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 2.59, indicating that its share price is 159% more volatile than the S&P 500.
Corbus Pharmaceuticals has a consensus price target of $74.60, suggesting a potential upside of 28.49%. Given Orgenesis' higher possible upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than Orgenesis.
In the previous week, Corbus Pharmaceuticals had 18 more articles in the media than Orgenesis. MarketBeat recorded 19 mentions for Corbus Pharmaceuticals and 1 mentions for Orgenesis. Corbus Pharmaceuticals' average media sentiment score of 1.87 beat Orgenesis' score of 0.81 indicating that Orgenesis is being referred to more favorably in the media.
Summary
Corbus Pharmaceuticals beats Orgenesis on 11 of the 15 factors compared between the two stocks.
Get Corbus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corbus Pharmaceuticals Competitors List
Related Companies and Tools
Free CRBP Stock Alerts